Skye Fund III Issues Letter Regarding Opposition to SomaLogic’s Proposed Merger with Standard BioToolsBelieves that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet
